THALES
3.11.2021 14:02:06 CET | Business Wire | Press release
In partnership with First Tech, global technology company Thales today announced it has helped venture capital-backed financial service provider SWAP launch its modern digital payment infrastructure. With Thales’s cloud-based payment transaction security solution, SWAP will deliver financial infrastructure technologies faster and more effectively to its banking-as-a-service customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005068/en/
Banking-as-a-Service
SWAP, a venture capital-backed financial service provider, was founded in 2018 to support fintech and service providers in the adoption of financial technology in response to demand across all sectors – from marketplaces to ride sharing – for more reliable transaction processing and expanded financial and payment services.
However, company expansion and customer satisfaction relied on in-built compliance with Payment Card Industry Data Standards (PCI DSS). As a start-up, SWAP wasn’t able to implement the entire technological infrastructure needed: a secure room would have slowed and complicated the launch process, and ultimately, SWAP needed to be able to provide accelerated, scalable, certified access to the market. First Tech and Thales’ solution grants SWAP the scalability and PCI certification it needs to grow as its customers do.
“Our solution, delivered collaboratively with First Tech, has proved instrumental in helping SWAP rapidly launch its product to market. SWAP’s lack of legacy systems meant that the team could leapfrog to providing the secure digital services their customers needed in a short amount of time, and this has translated to success for both SWAP and their customers. Thales has a rich heritage in being a trusted provider of solutions that protect the data and services businesses and end-users rely on. We look forward to continuing to support SWAP and its customers in their impressive growth,” said Todd Moore, VP Encryption Products at Thales.
Driving growth
First Tech’s hosted payShield Hardware Security Module (HSM) offers SWAP a cloud-based service with HSM off premises. Thales’ market-leading HSMs are highly scalable, providing the flexibility and agility needed to support SWAP in its future growth. The environment includes a secure room for insertion of keys, the support of trained professionals, team training, consultancy, and services.
Bruno Napolitano, CISO Security, Risk, and Fraud at SWAP explained, “Thales payShield 10K is considered the benchmark for payment HSMs, with an excellent performance and several global certifications that prove the reliability of the solution for PCI compliance. In fact, our credit card partner has confirmed this was the fastest implementation of card issuance they’ve undertaken in the past 15 years, which is testament to the solution at hand. This speed to market has already made a huge impact on our growth, and since launch, we’ve seen a four-fold increase in our customer portfolio. Looking ahead, we expect to accelerate our growth by 30% to 40% per year, always counting on the support from First Tech and Thales.”
Edmar Siqueira, Head of innovation, Digital Payments at First Tech added: “By working in tandem with Thales, we’ve been able to provide SWAP with a remote HSM management system which enables their business and their customers to benefit from operational cost savings, greater agility, and on-demand key management. Importantly, the success of this solution has been driven by both the strength of the product and the commitment from all parties to ensuring that the implementation process delivered a full-rounded understanding which will continue to serve SWAP well as it grows.
A bout Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Security
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005068/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
